Kaley Wilson

Kaley Wilson has a diverse work experience in various roles and organizations. In 2016, they worked as the Director of Business Development at Quark Venture. In 2020, they served as the Interim CEO of Sitka Biopharma. Kaley then became a Board Director for Crohn's and Colitis Canada, Canary Medical Inc., Microbion Corporation, and IOME (stealth mode) in 2021. In 2019, they were a member of the Commercialization Committee at GlycoNet and the Research Management Committee at https://www.nanomedicines.ca/. From 2018 to 2019, they held the position of Interim CEO at ARTMS Products Inc. Prior to that, they worked at The Centre for Drug Research and Development, starting as a Scientist in Project Evaluation from 2008 to 2010. Kaley then became the Manager of Business Development from 2010 to 2014 and later the Associate Director of Partnerships from 2014 to 2016.

Kaley Wilson obtained a PhD degree in Immunology, Biochemistry, and Cancer from The University of British Columbia. This education was completed between the years 2002 and 2007.